VAERS reports by lot

Pfizer COVID-19 lot 33025BD: VAERS reports

400 VAERS reports list lot 33025BD as a Pfizer COVID-19 vaccine, received between 2021-12-15 and 2024-10-03. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
400
Reports
8%
Marked serious
4
With a death outcome
22
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
General / Systemic (non-local)22121%
Neurological20419%
Cardiac / Cardiovascular14814%
Gastrointestinal11211%
Respiratory1009%
Musculoskeletal575%
Dermatological (non-injection-site)565%
Injection-site / Local reaction565%
Allergic / Anaphylactic505%
Psychiatric / Neuropsychiatric283%
Thrombotic / Hematological162%
Autoimmune / Immune-mediated71%
Reproductive / Menstrual40%

Where reports came from

U.S. state of the reporter, where given (top 12).

Colorado65
California61
Texas36
Kansas17
Michigan16
New York14
Illinois14
Indiana13
Wisconsin13
Washington10
New Jersey10
Georgia9

Reports by month received

2021-1273
2022-01126
2022-0286
2022-0319
2022-0432
2022-058
2022-064
2022-075
2022-084
2022-095
2022-103
2022-112
2022-127
2023-0111
2023-022
2023-057
2023-061
2023-071
2023-081
2024-011
2024-081
2024-101

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.